Key Takeaways
- Strong top-line, margin squeeze: Revenue grew 32% YoY on volume and market share gains, but gross margin contracted 371 bps to 50.1% as US pricing erosion and input cost inflation bit.
- Teva plant is the big bet: Integration starts 1 April; management expects nine months to breakeven and has budgeted ~INR200 crores overall, including the upfront payment, to expand capacity to 800 crore units.
- Balance sheet transformed: OrbiMed Asia now holds a 10.88% stake after a Rs. 372.40 crore warrant conversion, and the company completed a Rs. 32 crore buyback, reshaping the capital structure.
- Margin relief is coming, but with a lag: Freight costs have already softened and raw material costs are expected to improve as China reopens, but the benefit will only be visible post ~6 months once high-cost inventory clears.
- What to watch next quarter: The pace of Teva plant integration and capex deployment, whether the promised freight cost benefit actually adds the guided ~1%+ to margins, and any concrete progress on the inorganic European acquisition.
Teva Plant Acquisition & Integration
- Strategic rationale: The plant is described as a very important strategic acquisition at a decent price; it will service global demand and newer markets, and with the planned expansion will generate slightly more volume than the existing plant.
- Integration timeline: The company enters the plant on 1 April 2023; the first nine months will be a consolidation and integration phase, with capex investment to increase capacity and capabilities in different dosage forms.
- Breakeven expectation: Management expects about nine months to breakeven operations once they enter the plant.
- Capex commitment: Budgeted about INR200 crores overall, including the upfront acquisition payment; all of the 800 crore unit capacity expansion will happen at this plant.
- Revenue contribution: Revenue from the Teva plant will start from FY24; management expects Teva to give decent, sizable revenue maybe 12 months down the line.
- CMO contract: The company has a CDMO/CMO contract with Teva on existing products to ship out for the next 12 months, providing a base load during integration.
- No revenue in Q3: No revenue from the Teva plant was recorded in the current quarter because integration starts 1 April.
Mark Saldanha: "So obviously reason is because we have the Teva acquisition there, which we have done. And we'll be integrating this acquisition on 1st of April. So there were too many things to juggle. So we decided to go down this route, number one, I do believe it will be more economical."
Margin Dynamics & Cost Relief
- Gross margin hit: Gross margin fell 371 bps YoY to 50.1%, driven by high single-digit pricing erosion in the US and input cost inflation.
- EBITDA resilience: EBITDA margin held stable at 16.0% YoY because operating leverage offset the impact of high inflation.
- Freight cost relief: Freight costs have come off meaningfully and the benefit will kick in from Q4 onwards; management expects a margin improvement of slightly one-plus percent from this alone.
- Raw material lag: The raw material situation is expected to further improve now that China has opened up, but the cost advantage will likely be visible only post ~6 months because the company is sitting on high-cost inventory built up during the October-December China lockdowns.
- Inventory overhang: The company increased inventory holdings to ~6 months of raw materials and finished products at high cost to ensure contract servicing during China's standstill; this high-cost stock must clear before lower input costs flow through to margins.
- Pricing pressure mechanism: Price erosion happens when material prices decline rapidly; if material prices are stable, price erosion does not occur to that level, but falling raw material costs invite competitive pricing pressure on finished products.
- Backward integration margin promise: Management expects 200–300 basis points of margin expansion from the backward integration process, with API as a proportion of raw material rising from ~50% to ~80%.
Mark Saldanha: "That was a big burden, which was difficult - because freight is a very variable factor. So it's difficult to pass it on to our client or something of that stuff, because it may go up and may come down. So you can't keep going into the client saying, well, it's gone up one day, it's come down the other day."
US Market & Competitive Dynamics
- Growth drivers: QoQ ~12% growth in the US was partly due to flu season involvement, but also driven by how products move in certain seasons, markets, and timings; management plans to show this type of growth year-on-year.
- Market share gains: Gains are attributed to service, new product launches, positioning, and the product basket offered, making the company a preferred choice; management states these are not primarily due to price reductions.
- Channel destocking risk: Post-pandemic, post-flu season, and post-viral outbreak corrections in the US distribution channel are causing some slowdown and pricing desperation among companies, but management does not see a materialistic impact on unit movement, distribution, or value erosion presently.
- Store brand contracts: Typical contract length is normally two years; after two years nothing stops a customer from switching, but relationship, reliability, consistency, and support factors help win the next contract.
- Ibuprofen stability: Price erosion on aging products like Ibuprofen is very limited because it has already eroded substantially; the molecule is relatively stable in volumes and value, though if raw material prices keep falling, competition may exploit that and drive further pressure.
- Pipeline ambition: The 32-product pipeline can help achieve the objective of doubling US revenue over time, if all molecules see light.
Mark Saldanha: "Honestly, companies get a bit desperate in terms of pricing. But that said and done, we are confident of achieving our objectives and hitting our forecasted numbers."
Rx-to-OTC Strategy
- Opportunity: Products coming out of Rx and going into OTC give better value than normal generics; volumes grow much higher when a product becomes reachable for consumers at grocery stores.
- Regulatory gate: The switch is driven primarily by regulatory bodies; the company needs to work well in advance based on probability factors to not miss early-to-market strategies.
- Timeline: This is a long-term plan; months of visibility comes before filing, then the company waits for approvals; it files when visibility of an OTC switch is happening, not when the product is still Rx.
- Pipeline: The company is working on a few categories in both Europe and the US, but it is too early to discuss specifics.
Mark Saldanha: "It is driven by the regulatory primarily, but it's a push from bigger companies that go on, and instead of waiting and watching, you need to be more alert as to what's happening in the market... based on the probability factors, we need to start working well in advance, so that we don't miss the bus on the early-to-market strategies."
Backward Integration & API Strategy
- CDMO route chosen: The company is pursuing a CDMO strategy for API sourcing rather than acquiring a plant; management believes it will be more economical and provides control over cost factors and more stability in raw material pricing.
- DMF pipeline: The company is working on 10 DMFs presently; at least two or three are expected to be filed in calendar year 2023. DMFs will be filed in Marksans' name but using third-party facilities.
- Commercialization timeline: Post DMF filing, getting active raw material onto a license could take 6–9 months; the total timeline to commercialization is ~1.5 years.
- Margin impact: 200–300 basis points of margin expansion is reasonable to expect from the backward integration process, with API rising from ~50% to ~80% of raw material.
- Molecules in focus: Include cetirizine and some digestives.
Balance Sheet, Cash & Inorganic Growth
- OrbiMed stake: On 20 January 2023, the company completed raising Rs. 372.40 crores via warrant conversion into equity shares by OrbiMed Asia and Promoters at Rs. 74/share; OrbiMed Asia now owns a 10.88% stake and has a board representative, Dr. Sunny Sharma.
- Buyback: In January 2023, the company completed a buyback of 64.74 lakh equity shares for Rs. 32 crores.
- Cash priorities: The company has a capex plan, needs to pay for the Teva deal (maybe in the next couple of weeks), will spend on the Teva capex plan, and is pursuing an inorganic growth strategy.
- European acquisition: Management is looking at expanding the footprint into Europe and is in dialogue with a couple of companies, but nothing is concrete; OrbiMed is involved in the process, providing insights on company backgrounds, financials, and analytic evaluations.
- Working capital: The working capital cycle is around 150 days and inventory days have risen to ~200 days because, after acquiring Time-Cap in the US, the company now distributes directly to end customers (B2C), so finished goods inventory stays on its books until delivery. Management expects these levels to continue.
Mark Saldanha: "M&A is a very tricky thing, but if past history has taught us anything, I mean if you look at our track records, we have done over four M&As over the span of a decade and a half. ... we have marathon discussions that puts valuable because they do give us insights of the company, the financial backgrounds, and analytic evaluations that they run through."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue milestone | Cross Rs. 2,000 crores | FY24 |
| EBITDA margin | Maintain margin, if not slightly improve | FY24 |
| Teva plant breakeven | Breakeven operations | ~9 months from 1 April 2023 entry |
| Teva plant capex | ~INR200 crores overall (including upfront payment) | Deployment during integration phase |
| Teva plant revenue | Decent, sizable revenue from Teva | ~12 months down the line |
| Freight cost margin benefit | Margin improvement of slightly one-plus percent | Q4 FY23 onwards |
| Raw material cost benefit | Lower input costs flow through | Post ~6 months (once high-cost inventory clears) |
| Backward integration margin impact | 200–300 bps expansion | As DMFs are filed and commercialized (~1.5 years) |
| DMF filings | At least 2–3 DMFs filed | Calendar year 2023 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Operating revenue | ₹479.8 cr, +32.3% YoY |
| US & North America revenue | ₹217.0 cr, +37.8% YoY |
| EU & UK formulation revenue | ₹186.8 cr, +25.4% YoY |
| Australia & New Zealand revenue | ₹49.6 cr, +27.6% YoY |
| Rest of World revenue | ₹26.5 cr, +52.0% YoY |
| Gross margin | 50.1%, declined 371 bps YoY from 53.8% |
| EBITDA | ₹76.6 cr, +32.6% YoY |
| EBITDA margin | 16.0%, stable YoY |
| Profit after tax | ₹62.3 cr, +29.1% YoY |
| EPS | ₹1.56, +30% YoY |
| Net cash position | ₹417 cr, debt-free as of 31 Dec 2022; excludes ₹279 cr warrant subscription received Jan 2023 |
| R&D spend (9M FY23) | ₹24.5 cr, 1.8% of sales |
| US business QoQ growth | ~12% |
| Own-label brands share | 15% to 20% of OTC business |
| Inventory | ~₹450 cr as of 31 Dec 2022 |
| Working capital cycle | ~150 days as of Dec 2022 |
| Issued share capital | ~45 cr shares post-warrant conversion and buyback |
| FY24 revenue guidance | Crossing ₹2,000 cr |
| Teva plant capex budget | ~₹200 cr, including upfront acquisition payment |
| Teva plant breakeven timeline | ~9 months from integration starting 1 Apr 2023 |
| UK pipeline | 34 new filings planned over next 3 years; 7 planned in CY2023; 16 already filed or awaiting approval |
| US pipeline | 32 products in pipeline; 20 solid oral, others in ointments, creams, soft gels |
| DMFs in development | 10 DMFs; at least 2-3 to be filed in 2023 |
| Freight cost margin benefit expected | Slightly 1%+ margin improvement from Q4 onwards |